Endowed & Emeritus

Endowed & Emeritus

Endowment Chair - Swami Rama Chair for Cancer Research
The Rappaport Family Technion Integrated Cancer Center (R-TICC) Technion-Israel Institute of Technology, Israel
Endowment Chair - Translational Research in Bio Sciences
Ministry of Chemicals & Fertilizers, Govt. of India
Endowment Chair - Research in Breast Cancer in young women
United States of America
Visiting Professor – Community Medicine
United Kingdom
Visiting Professor – Research
LBSNAA, Mussoorie
Visiting Professor – Incubation Centre
Directorate of Industries, Government of Uttarakhand
Visiting Professor – Incubation Centre
New Delhi
Professor Emeritus
Chairman, ASRB, New Delhi
Visiting Professor
Institute for Leprosy and OMD (ICMR)
Professor Emeritus
Former Fellow, Dept. of Economics & Accounting, Liverpool, UK
Head, Devi Ahilya University, Indore
Admissions Open for 2025

Admission Open For 2025

×
Nobel Laureate
Prof. Aaron Ciechanover

Prof. Ciechanover is currently a Distinguished Research Professor in the Faculty of Medicine at the Technion – Israel Institute of Technology, also located in Haifa. He earned his M.Sc. in 1971 and his M.D. in 1973 from the Hebrew University of Jerusalem. Following his national service as a military physician from 1973 to 1976, he pursued a doctorate in biological sciences at the Technion, receiving his D.Sc. in 1982.

As a graduate student under the mentorship of Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose of the Fox Chase Cancer Center in Philadelphia, Ciechanover co- discovered the pivotal role of ubiquitin in protein degradation. Their research demonstrated that attaching ubiquitin covalently to target proteins acts as a signal for their destruction. They explained the mechanism of ubiquitin conjugation, revealed the system's general proteolytic functions, and proposed a model in which ubiquitin modification serves as a recognition tag for a specific downstream protease.

While continuing his research as a postdoctoral fellow with Dr. Harvey Lodish at Massachusetts Institute of Technology (MIT), Ciechanover made further significant contributions to understanding the ubiquitin system (h-index 117, citations >84,000). Over time, it became clear that ubiquitin-mediated proteolysis is vital to many cellular processes. Disruption of this system has been linked to various diseases, including cancers and neurodegenerative disorders, making it a crucial target for drug development.

Ciechanover’s groundbreaking work has earned him numerous prestigious awards, including the Albert Lasker Award (2000), the EMET Prize (2002), the Israel Prize (2003), and the Nobel Prize in Chemistry (2004), which he shared with Drs. Hershko and Rose.

He is a member of numerous esteemed academic institutions, including the Israeli National Academy of Sciences and Humanities, the European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, and the U.S. National Academies of Sciences and Medicine (Foreign Associate). He also holds international memberships in the Pontifical Academy of Sciences, the Chinese Academy of Sciences, the Russian Academy of Sciences, and the German Academy of Sciences Leopoldina.

Founder and CEO

Prof. Rakesh Kumar

Prof. Rakesh Kumar is the Founder and President of the Breast Cancer in Young Women Foundation (USA), dedicated to addressing the distinct issues affecting young women with breast cancer. He also serves as the International Endowed Chair Professor at the Cancer Research Institute of the Himalayan Institute of Medical Sciences. Additionally, he holds adjunct professorships at Rutgers New Jersey Medical School and Virginia Commonwealth University.

Dr. Kumar earned his Ph.D. from the All India Institute of Medical Sciences in 1984 and began his research career at Memorial Sloan Kettering Cancer Center in January 1986. From 1988 to 2017, he held various academic and leadership positions —including faculty member, tenured professor, distinguished professor, endowed chair, department chair, and research leader—at esteemed institutions such as Memorial Sloan Kettering Cancer Center in New York and the University of Texas MD Anderson Cancer Center in Houston. From 2017 to 2022, he served as the National Chair for Cancer Research for the Government of India and as a distinguished professor, continuing his innovative work in breast cancer research.

With nearly 40 years of research and professional experience, Dr. Kumar has made conceptual contributions to the field of cancer research (h-index 108, citations >50,000). He has authored over 325 peer-reviewed publications, edited or co-edited nine books, and delivered 290 invited lectures worldwide. His work has been featured on the covers of 18 major cancer journals and has been highlighted in institutional research reports of the MD Anderson Cancer Center.

A passionate educator and mentor, Dr. Kumar has guided 67 trainees throughout his career. He serves on the editorial boards of multiple leading cancer journals and has served on the editorial boards of 21 top cancer journals. His global reputation is further demonstrated by his participation in about 100 peer-review panels for cancer research funding in the US and internationally over the past 28 years.

Dr. Kumar's innovative research has earned him numerous prestigious honors, including the Hinkle Society Faculty Award at Penn State University (1994), the Dalla/Fort Worth Living Legend Faculty Achievement Award in Basic Sciences (2004), the Ranbaxy Research Award (2006), and the Lifetime Achievement Award from the American Association of Indian Scientists in Cancer Research (2013), among others. Dr. Kumar's pioneering research continues to have a profound influence on the fields of oncology and breast cancer, opening up new opportunities for biomedical scientists and trainees worldwide.